Cargando…

The CD36-PPARγ Pathway in Metabolic Disorders

Uncovering the biological role of nuclear receptor peroxisome proliferator-activated receptors (PPARs) has greatly advanced our knowledge of the transcriptional control of glucose and energy metabolism. As such, pharmacological activation of PPARγ has emerged as an efficient approach for treating me...

Descripción completa

Detalles Bibliográficos
Autores principales: Maréchal, Loïze, Laviolette, Maximilien, Rodrigue-Way, Amélie, Sow, Baly, Brochu, Michèle, Caron, Véronique, Tremblay, André
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983591/
https://www.ncbi.nlm.nih.gov/pubmed/29883404
http://dx.doi.org/10.3390/ijms19051529
_version_ 1783328452733042688
author Maréchal, Loïze
Laviolette, Maximilien
Rodrigue-Way, Amélie
Sow, Baly
Brochu, Michèle
Caron, Véronique
Tremblay, André
author_facet Maréchal, Loïze
Laviolette, Maximilien
Rodrigue-Way, Amélie
Sow, Baly
Brochu, Michèle
Caron, Véronique
Tremblay, André
author_sort Maréchal, Loïze
collection PubMed
description Uncovering the biological role of nuclear receptor peroxisome proliferator-activated receptors (PPARs) has greatly advanced our knowledge of the transcriptional control of glucose and energy metabolism. As such, pharmacological activation of PPARγ has emerged as an efficient approach for treating metabolic disorders with the current use of thiazolidinediones to improve insulin resistance in diabetic patients. The recent identification of growth hormone releasing peptides (GHRP) as potent inducers of PPARγ through activation of the scavenger receptor CD36 has defined a novel alternative to regulate essential aspects of lipid and energy metabolism. Recent advances on the emerging role of CD36 and GHRP hexarelin in regulating PPARγ downstream actions with benefits on atherosclerosis, hepatic cholesterol biosynthesis and fat mitochondrial biogenesis are summarized here. The response of PPARγ coactivator PGC-1 is also discussed in these effects. The identification of the GHRP-CD36-PPARγ pathway in controlling various tissue metabolic functions provides an interesting option for metabolic disorders.
format Online
Article
Text
id pubmed-5983591
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-59835912018-06-05 The CD36-PPARγ Pathway in Metabolic Disorders Maréchal, Loïze Laviolette, Maximilien Rodrigue-Way, Amélie Sow, Baly Brochu, Michèle Caron, Véronique Tremblay, André Int J Mol Sci Review Uncovering the biological role of nuclear receptor peroxisome proliferator-activated receptors (PPARs) has greatly advanced our knowledge of the transcriptional control of glucose and energy metabolism. As such, pharmacological activation of PPARγ has emerged as an efficient approach for treating metabolic disorders with the current use of thiazolidinediones to improve insulin resistance in diabetic patients. The recent identification of growth hormone releasing peptides (GHRP) as potent inducers of PPARγ through activation of the scavenger receptor CD36 has defined a novel alternative to regulate essential aspects of lipid and energy metabolism. Recent advances on the emerging role of CD36 and GHRP hexarelin in regulating PPARγ downstream actions with benefits on atherosclerosis, hepatic cholesterol biosynthesis and fat mitochondrial biogenesis are summarized here. The response of PPARγ coactivator PGC-1 is also discussed in these effects. The identification of the GHRP-CD36-PPARγ pathway in controlling various tissue metabolic functions provides an interesting option for metabolic disorders. MDPI 2018-05-21 /pmc/articles/PMC5983591/ /pubmed/29883404 http://dx.doi.org/10.3390/ijms19051529 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Maréchal, Loïze
Laviolette, Maximilien
Rodrigue-Way, Amélie
Sow, Baly
Brochu, Michèle
Caron, Véronique
Tremblay, André
The CD36-PPARγ Pathway in Metabolic Disorders
title The CD36-PPARγ Pathway in Metabolic Disorders
title_full The CD36-PPARγ Pathway in Metabolic Disorders
title_fullStr The CD36-PPARγ Pathway in Metabolic Disorders
title_full_unstemmed The CD36-PPARγ Pathway in Metabolic Disorders
title_short The CD36-PPARγ Pathway in Metabolic Disorders
title_sort cd36-pparγ pathway in metabolic disorders
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983591/
https://www.ncbi.nlm.nih.gov/pubmed/29883404
http://dx.doi.org/10.3390/ijms19051529
work_keys_str_mv AT marechalloize thecd36ppargpathwayinmetabolicdisorders
AT laviolettemaximilien thecd36ppargpathwayinmetabolicdisorders
AT rodriguewayamelie thecd36ppargpathwayinmetabolicdisorders
AT sowbaly thecd36ppargpathwayinmetabolicdisorders
AT brochumichele thecd36ppargpathwayinmetabolicdisorders
AT caronveronique thecd36ppargpathwayinmetabolicdisorders
AT tremblayandre thecd36ppargpathwayinmetabolicdisorders
AT marechalloize cd36ppargpathwayinmetabolicdisorders
AT laviolettemaximilien cd36ppargpathwayinmetabolicdisorders
AT rodriguewayamelie cd36ppargpathwayinmetabolicdisorders
AT sowbaly cd36ppargpathwayinmetabolicdisorders
AT brochumichele cd36ppargpathwayinmetabolicdisorders
AT caronveronique cd36ppargpathwayinmetabolicdisorders
AT tremblayandre cd36ppargpathwayinmetabolicdisorders